In vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.
Plasmodium falciparum Pfcrt-76 and Pfmdr1-86 gene polymorphisms were determined during a clinical trial in Burkina Faso comparing the efficacies of dihydroartemisinin-piperaquine (DHA-PPQ) and artemether-lumefantrine (AL). Significant selection of Pfcrt-K76 was observed after exposure to AL and DHA-PPQ, as well as selection of Pfmdr1-N86 after AL but not DHA-PPQ treatment, suggesting reverse selection on the Pfcrt gene by PPQ. These results support the rational use of DHA-PPQ in settings where chloroquine (CQ) resistance is high.
National Institute for Medical Research, Tanga Medical Research Centre, Tanga, United Republic of Tanzania International Health Unit, Department of Epidemiology, University of Antwerp, Antwerp, Belgium vitobaraka@gmail.com.
Vito
V
Baraka
Centre Muraz, Bobo Dioulasso, Burkina Faso.
Halidou
H
Tinto
Centre Muraz, Bobo Dioulasso, Burkina Faso.
Innocent
I
Valea
Malariology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Robert
R
Fitzhenry
International Health Unit, Department of Epidemiology, University of Antwerp, Antwerp, Belgium.
Christopher
C
Delgado-Ratto
International Health Unit, Department of Epidemiology, University of Antwerp, Antwerp, Belgium Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda.
Martin K
MK
Mbonye
Malariology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Chantal
C
Van Overmeir
Malariology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Anna
A
Rosanas-Urgell
International Health Unit, Department of Epidemiology, University of Antwerp, Antwerp, Belgium.
Jean-Pierre
JP
Van Geertruyden
Malariology Unit, Institute of Tropical Medicine, Antwerp, Belgium Medical Research Council, Banjul, the Gambia London School of Hygiene and Tropical Medicine, London, United Kingdom.
Umberto
U
D'Alessandro
Malariology Unit, Institute of Tropical Medicine, Antwerp, Belgium.
Annette
A
Erhart
D018692:Antimanic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000008:administration & dosage / Q000627:therapeutic use*; D002050:Burkina Faso / Q000453:epidemiology; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics; D004983:Ethanolamines / Q000627:therapeutic use*; D005449:Fluorenes / Q000627:therapeutic use*; D014644:Genetic Variation / Q000187:drug effects / Q000235:genetics; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D026901:Membrane Transport Proteins / Q000235:genetics*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*; D010963:Plasmodium falciparum / Q000187:drug effects / Q000235:genetics*; D015800:Protozoan Proteins / Q000235:genetics*; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D010879:Piperazines
D018692:Antimanic Agents; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes; D026901:Membrane Transport Proteins; D027425:ATP-Binding Cassette, Sub-Family C Proteins; D015800:Protozoan Proteins; D011804:Quinolines; C513498:Mdr1 protein, Plasmodium falciparum; C416369:PfCRT protein, Plasmodium falciparum; C039060:artenimol; C034759:piperaquine; D010879:Piperazines